Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Corporate Update (September 2026)
23 slides from Invivyd's corporate update, Sep 29, 2026
Slide 1: Topline LIBERTY Data & VYD2311 Next Steps
Topline LIBERTY Data & VYD2311 Next Steps September 29, 2026 ©2026 Invivyd, Inc. Invivyd is a registered trademark of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A
Slide 4: Invivyd Vision
Invivyd Vision Antibody supplementation as a new step forward in the human fight against infectious disease 4
Slide 5: Executive summary: VYD2311 met all endpoints in LIBERTY
VYD2311 met all primary and secondary endpoints in the Phase 3 LIBERTY study, with a clinically and statistically superior safety and tolerability profile relative to an mRNA COVID-19 vaccine VYD2311 observed profile in LIBERTY indicates high measured neutralizing antiviral activity supporting the t
Slide 6: Agenda
agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A
Slide 7: LIBERTY Phase 3 study design
RAT: Rapid Antigen Test; BMI: body mass index. Note: mRNA vaccine COMIRNATY® (COVID-19 vaccine, mRNA) was utilized in the LIBERTY study. All subjects were dosed using intramuscular needles consistent with COVID-19 vaccination, and, for blinding purposes, placebo injections were volume-matched to eit
Slide 8: Baseline characteristics well-balanced across LIBERTY arms
Baseline characteristics were well-balanced across LIBERTY study arms VYD2311 Only (N=69) Vaccine Only (N=70) Combination (N=71) Sex (% Female) 41% 50% 39% Age (Years) - Mean 34.9 33.8 35.4 Race (%) White (%) 46% 44% 42% Black (%) 42% 44% 49% Other & Unknown (%) 12% 12% 9% Weight (kg) - Mean 77.2 77
Slide 9: VYD2311 monotherapy met both co-primary endpoints versus mRNA vaccine
VYD2311 monotherapy met both co-primary endpoints when compared to an mRNA-based COVID-19 vaccine TEAE: treatment-emergent adverse event; ISR: injection site reaction; AE: adverse event. Note: mRNA vaccine COMIRNATY® (COVID-19 vaccine, mRNA) was utilized in the LIBERTY study. No hypersensitivity or
Slide 10: Adding VYD2311 to mRNA vaccine may improve tolerability
The addition of VYD2311 to an mRNA COVID-19 vaccine may improve the safety and tolerability of the mRNA COVID vaccine alone Co-Primary Endpoints Treatment Arm (% of Subjects) Comparator Arm (% of Subjects) P-value Short Term (6 Days) Overall Safety and Tolerability % of subjects experiencing any TEA
Slide 11: VYD2311 demonstrated benefit across multiple endpoints
VYD2311 demonstrated benefit compared to mRNA COVID-19 vaccine across multiple endpoints VYD2311 mRNA COVID-19 Vaccine Combination Subjects with Event (%) Adverse Event Incidence by Arm: First 7 Days
Slide 12: Assessment of immunologic interference experimental design
Assessment of immunologic interference experimental design Clinical Sample from VYD2311 & COVID-19 Vaccine Combination Arm VYD2311 + anti-VYD2311 Complex (REMOVED) Vaccine-Induced Titers Only from Combination Sample for Comparison to Vaccine-Only Samples Add anti-VYD2311 Antibody & Perform Separatio
Slide 13: Combination delivery shows no effect on vaccine-derived neutralizing response
Combination delivery of VYD2311 and mRNA-based COVID vaccine appears to have no effect on vaccine-derived neutralizing response and to increase total titers *Both arms identically treated with VYD2311 depleting reagents.
Slide 14: Key takeaways & implications
VYD2311 exhibited more favorable safety and tolerability compared to the mRNA COVID-19 vaccine, supporting the potential for VYD2311 to offer a clinically meaningful advantage over the current standard-of-care No evidence of immunologic interference was observed between VYD2311 and mRNA COVID-19 vac
Slide 15: Agenda
agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A
Slide 16: VYD2311 is the latest in a series of clinically-validated antibodies
Recall VYD2311 is simply the latest in a series of functionally identical, clinically-validated Invivyd monoclonal antibodies Adintrevimab Fv Bound to Wuhan (WT) RBD Pemivibart Fv Bound to Omicron BA.5 RBD VYD2311 Fv Bound to XEC RBD 71% Reduction in risk of symptomatic COVID-19 at 90 days* 94% Redu
Slide 17: Binding and neutralization geometrically identical across Invivyd antibodies
Binding and neutralization across all Invivyd COVID antibodies is geometrically identical at the level x-ray crystallography Adintrevimab, Pemivibart, and VYD2311 Superimposed on Target: +/- 0.5A Each COVID mAb was minimally evolved to ensure the preservation of the clinically-validated biological i
Slide 18: Antiviral titers as reliable predictors of clinical protection
We believe as a consequence that the resulting antiviral titers from our antibodies are highly reliable predictors of clinical protection The relationship between neutralizing titers and protection from symptomatic COVID-19 is now well established in two peer-reviewed correlate-of-protection analyse
Slide 19: VYD2311 meets and exceeds criteria for Accelerated Approval
We believe VYD2311 meets and exceeds the criteria for Accelerated Approval IC: Immunocompromised; EUA: Emergency Use Authorization; sVNA: serum virus neutralizing antibody. Sources: FDA. “ Guidance Document: Accelerated Approval – Expedited Program for Serious Conditions” Published December 2024. Fa
Slide 20: Preparations underway for VYD2311 Accelerated Approval BLA submission
Preparations underway for VYD2311 Accelerated Approval BLA submission Unblind and report the placebo-controlled safety and immunogenicity data from DECLARATION Move to submitting Biologics License Application (BLA) as soon as possible Continue commercial preparation for VYD2311 20
Slide 21: Agenda
agenda Executive Summary LIBERTY Topline Data Regulatory & Next Steps Q&A
Slide 22: Invivyd Inc.
INVIVYD INC.
Slide 23: Invivyd Inc.
| INVIVYD INC. |